Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) traded up 2.2% during trading on Monday . The company traded as high as $19.46 and last traded at $18.52, with a volume of 307,212 shares changing hands. The stock had previously closed at $18.12.

A number of equities research analysts have recently commented on the company. Piper Jaffray Cos. reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Saturday, July 9th. Citigroup Inc. upgraded Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, August 9th. Zacks Investment Research downgraded Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th. Jefferies Group increased their price objective on Bellicum Pharmacueticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Finally, SunTrust Banks Inc. assumed coverage on Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price objective for the company. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. Bellicum Pharmacueticals currently has an average rating of “Buy” and an average price target of $27.00.

The stock’s 50 day moving average price is $15.95 and its 200-day moving average price is $11.85. The firm’s market capitalization is $504.45 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.04. During the same period in the prior year, the business earned ($0.40) EPS. Equities research analysts expect that Bellicum Pharmacueticals Inc. will post ($2.32) EPS for the current fiscal year.

In related news, insider Kevin M. Slawin sold 67,000 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $19.31, for a total value of $1,293,770.00. Following the completion of the sale, the insider now owns 100,079 shares of the company’s stock, valued at $1,932,525.49. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CTO Kevin M. Slawin sold 2,719 shares of the firm’s stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $13.99, for a total transaction of $38,038.81. Following the completion of the sale, the chief technology officer now directly owns 134,206 shares of the company’s stock, valued at approximately $1,877,541.94. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley raised its position in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent quarter.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.